Lp(a) lowering with PCSK9 inhibitor not enough to tackle artery wall inflammation - PACE-CME

Lpa lowering with PCSK inhibitor not enough to tackle artery wall inflammation

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Finerenone does not alter vascular stiffness in patients with T2D and CKD
Finerenone does not alter vascular stiffness in patients with T2D and CKD
ESC Heart Failure 2025
Finerenone does not alter vascular stiffness in patients with T2D and CKD
- Atsushi Tanaka, MD, PhD
Perspectives on CKM syndrome
Perspectives on CKM syndrome
AHA 2024
Perspectives on CKM syndrome
- Javed Butler, MD
Exciting times to address residual inflammatory risk
Exciting times to address residual inflammatory risk
EAS 2024
Exciting times to address residual inflammatory risk
- Peter Libby, MD
The role of inflammation in atherosclerosis
The role of inflammation in atherosclerosis
Inflammation
The role of inflammation in atherosclerosis
- Peter Libby, MD